The compound with CAS number 1231930-37-2 is a key synthetic intermediate in the production of Abemaciclib (LY2835219), a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Abemaciclib is an active pharmaceutical ingredient (API) approved for the treatment of certain types of advanced or metastatic breast cancer. As a designated intermediate ("LY2835219 intermediate III"), this compound is specifically designed and synthesized for the multi-step construction of the Abemaciclib molecule. Its structure contains functional groups and a core heterocyclic scaffold that are crucial for the final API's biological activity. The synthesis and quality control of this intermediate are critical steps in the commercial manufacturing process of the drug. This intermediate is not a general-purpose building block but a highly specialized chemical entity. Its primary and almost exclusive application is within the pharmaceutical supply chain for the synthesis of Abemaciclib, underscoring its role as a vital component in oncology drug development and production.